logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A cost-minimization of heart failure therapy with bisoprolol in the French setting : An analysis from CIBIS trial data.

    Article - En anglais

    Beta-blocker-induced benefit in heart failure is under intense evaluation.

    Several large-scale mortality trials are currently being performed, with CIBIS II evaluating bisoprolol.

    The economic impact of beta-blocker therapy in heart failure has not been previously determined.

    The present study is a cost-effectiveness evaluation of bisoprolol treatment based on CIBIS I data.

    It considers direct costs, that is, the bisoprolol medication cost and the cost of hospitalization related to heart failure and its complications.

    Hospitalization costs were calculated from the French system of classification (PMSI), which provides costs according to homogeneous groups of patients (GHM).

    The cost difference between bisoprolol and placebo in the entire CIBIS population and the trial duration result from an increase in cost caused by bisoprolol treatment (+2018 Frs/patient) and a decrease in cost related to reduced hospitalization (6349 Frs/patient).

    A total savings per patient of about 4330 Frs was produced by bisoprolol.

    Cost reduction is still more pronounced in patients not having a history of myocardial infarction.

    We conclude that heart failure therapy with bisoprolol lowers medical healthcare costs, mainly due to the reduced rate of hospital admissions for heart failure.

    Mots-clés Pascal : Bisoprolol, Antihypertenseur, Bloquant bêta-adrénergique, Analyse coût efficacité, Mortalité, Insuffisance cardiaque, Economie santé, Hospitalisation, Complication, Prévention, Traitement, Chimiothérapie, Homme, In vivo, Placebo, Minimisation coût, Appareil circulatoire pathologie, Cardiopathie

    Mots-clés Pascal anglais : Bisoprolol, Antihypertensive agent, Beta blocking agent, Cost efficiency analysis, Mortality, Heart failure, Health economy, Hospitalization, Complication, Prevention, Treatment, Chemotherapy, Human, In vivo, Placebo, Cost minimization, Cardiovascular disease, Heart disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0013804

    Code Inist : 002B02F09. Création : 31/05/1999.